Archive

ShareThis Page
Bayer increases marketing, research operations to expand foothold in U.S. | TribLIVE.com
U.S./World

Bayer increases marketing, research operations to expand foothold in U.S.

The Associated Press
| Saturday, April 2, 2016 5:36 p.m
APTOPIXBayerUSExpansionJPEG0886e
Carolyn King (right) and Regin Trinidad package vials of the drug Kogenate FS, a medicine used by people with hemophilia, on Monday, May 18, 2015, at Bayer Corp[ labs in Berkeley, Calif.

WHIPPANY, N.J. — The German conglomerate that invented aspirin more than a century ago wants to take over more of your medicine cabinet.

Bayer AG is boosting its presence and brand in the United States, the world’s biggest medicine market. It is increasing everything from marketing and research operations in the U.S., to the number of its nonprescription medicines in pharmacies and grocery stores.

The U.S. expansion is part of the 153-year-old company’s transformation from a chemical-and-dye manufacturer — a business it spun off last year — to a pure “life sciences” company focused on the health of people, pets and plants.

“I hope that over the next few years, people will learn that Bayer is more than aspirin,” said Phil Blake, Bayer’s U.S. president and head of pharmaceuticals for the Americas.

Bayer’s strategy is a departure in an industry in which companies typically swim together in the same direction. Bayer is focused on expanding in the United States while other top drugmakers are concentrating on increasing sales and manufacturing in Asia and other developing markets.

The world’s 14th-biggest drugmaker has seen signs its strategy is paying off. Last year, Bayer’s sales jumped 28 percent to about $14 billion in the U.S. and Canada, where consumer health sales soared 66 percent and prescription drug sales jumped 23 percent. Global revenue rose 12 percent to nearly $51 billion.

“The U.S. is the most important country for Bayer,” said global innovation chief Kemal Malik.

Bayer, based in Leverkusen, Germany, boosted its research budget last year 21 percent to $4.7 billion. It’s doing more in two areas rivals have mostly abandoned despite huge unmet need and millions of patients: heart disease and women’s health.

Bayer is doing more research collaborations in the United States, such as its deal with Johns Hopkins University to develop medicines for vision-damaging diseases. It has a partnership with Massachusetts startup CRISPR Therapeutics to develop therapies for blood disorders, blindness and other conditions.

Across America, Bayer has been hiring hundreds of scientists, factory workers and salespeople, and enlarging or building research labs, offices and medicine factories.

It funds a San Francisco “incubator” that houses startups developing experimental medicines and related technology. It’s pouring $1 billion into new greenhouses, factories for crop-protecting chemicals and development of seeds that can withstand climate change.

Medical breakthrough?

Bayer hopes its newest medicines — cancer drugs Xofigo and Stivarga, Xarelto for preventing blood clots, Eyelea for preventing blindness and Adempas for high blood pressure in lungs — will reinvigorate its U.S. prescription drug business. That business had declined after Bayer’s 2001 recall of a cholesterol drug linked to patient deaths.

Bayer is a leader in women’s health, selling Yaz, Yasmin and other birth control pills; Mirena and other intrauterine devices, and Essure, an implant for permanently preventing pregnancy. Last month, U.S. regulators required that Essure bear its strictest warning, noting chronic pain and bleeding in some users, and ordered Bayer to conduct new safety studies.

The company has become a contender in cancer medicines, jumping from one a decade ago to three today, with two dozen more in patient testing, innovation chief Malik said. Meanwhile, under a new partnership with the American Association for Cancer Research, Bayer will give U.S. scientists grants to transform ideas for new cancer targets into medicines.

Marijn Dekkers, Bayer’s CEO since 2010, anticipates multiple study results during the next year will spawn several drug approvals for conditions including heart failure, lung infections and kidney disease. In February, American regulators approved Bayer’s Kovaltry, a drug that reduces bleeding episodes in hemophilia patients.

“We have a lot of upside potential,” said Dekkers, who retires on May 1 and will be succeeded by Bayer’s strategy chief, Werner Baumann.

To lift its profile among U.S. consumers, Bayer boosted its marketing and social media efforts.

It’s been running TV ads for 17 consumer brands, double its 2010 total. It’s offering discount coupons online and in newspapers. And it has put the Bayer cross logo, previously reserved for its aspirin, on all products.

Bayer has doubled its social media staff, started an Instagram page, added U.S. content to its Facebook page and increased its Twitter posts sevenfold, with product and other news, quizzes and links to sites offering product coupons and tips on related disorders.

Erik Gordon, an assistant professor at University of Michigan’s Ross School of Business, said Bayer can raise its U.S. sales significantly with its larger product lineup and increased marketing. Meanwhile, its metamorphosis to a pure life sciences company should boost research productivity.

“They’re more likely to have a bright future by doing this than not,” Gordon said.

Taking more shelf space

A key part of Bayer’s U.S. strategy is expanding its consumer health business.

That’s been driven by its 2014 purchase of Merck & Co.’s consumer health unit for $14.2 billion.

Iconic Bayer aspirin, patented in 1899, holds 62 percent of U.S. market share among aspirin brands. Sales are still growing, up 7 percent last year to $520 million worldwide.

Pain relievers and vitamins aren’t sexy, but they have appeal: Development costs are low, advertising can quickly boost sales, products attract few lawsuits compared with prescription drugs, and they sell steadily for decades.

Bayer markets 170 consumer health products, 17 with annual sales topping $100 million. Those include Bayer’s One-A-Day and Flintstones vitamins, Aleve pain reliever, and Phillips’ Colon Health, plus former Merck products including Claritin, Coppertone and Dr. Scholl’s foot products.

The expanded consumer health portfolio now holds more prized eye-level supermarket and pharmacy shelf space, which boosts sales. Bayer now markets the former Merck brands worldwide, which helped it increase total consumer health sales 30 percent last year.

Categories: Wire stories
TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.